Are Analysts Bullish about Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) after last week?

June 17, 2018 - By Adrian Mccoy

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Ratings Coverage

Among 6 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals had 7 analyst reports since December 20, 2017 according to SRatingsIntel. H.C. Wainwright maintained Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) rating on Tuesday, February 13. H.C. Wainwright has “Buy” rating and $12.0 target. H.C. Wainwright maintained Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) rating on Wednesday, December 20. H.C. Wainwright has “Buy” rating and $9.0 target. The rating was maintained by JMP Securities with “Buy” on Monday, March 19. Below is a list of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) latest ratings and price target changes.

04/05/2018 Broker: Cowen & Co Rating: Outperform Initiates Coverage On
19/03/2018 Broker: JMP Securities Rating: Buy New Target: $9.0 Maintain
19/03/2018 Broker: Evercore Rating: Outperform New Target: $13 Initiates Coverage On
19/03/2018 Broker: Jefferies Rating: Buy New Target: $12 Initiates Coverage On
13/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0 Maintain
17/01/2018 Broker: William Blair Rating: Outperform Initiates Coverage On
20/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain

The stock decreased 2.82% or $0.15 during the last trading session, reaching $5.17. About 652,177 shares traded or 17.62% up from the average. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 40.22% since June 17, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $279.05 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.